| P/E (FY) | 3.3 | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | 55.06% |
| Net Margin | 70.05% | ROIC | 68.60% |
| Debt / Equity | 0.02 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 345.83% |
Zealand Pharma is a biotechnology company that discovers, develops, and commercializes peptide-based medicines in Denmark and the United States, concentrating on gastrointestinal and metabolic diseases and other areas of unmet need. Marketed products include Zegalogue for severe hypoglycemia, while its pipeline features dasiglucagon for congenital hyperinsulinism and glepaglutide, a long-acting GLP-2 analog in Phase III trials for short bowel syndrome. The company is based in Søborg, Denmark.
| Market Cap | — | Trading Days | 3864 |
| 52W High | 556.00 |
| 52W Low | 233.50 |
| % Off High | −46.22% |
| YTD | −35.89% | 1Y | −20.84% |
| 3Y | 35.79% | 5Y | 63.30% |
| 10Y | 151.26% | Since incept. (ann.) | 8.27% |
| Ann. Volatility (1Y) | 69.13% | Ann. Volatility (3Y) | 66.69% |
| Sharpe (1Y) | 0.03 | Sharpe (3Y) | 0.50 |
| Max Drawdown (1Y) | −56.96% | Max Drawdown (3Y) | −75.38% |
| Beta (3Y, vs SPY) | 1.30 |
No same-industry peers in the universe for ZEAL.CO.
